# Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Source: https://onco.cc/trials/nct03016819/  
OnCo record `nct03016819` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Anlotinib, Dacarbazine in sarcomas, run by Advenchen Laboratories, LLC, now recruiting.

## Summary

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) is a phase 3 interventional study registered as NCT03016819 by Advenchen Laboratories, LLC, with 325 participants planned, started 2017-08-15 and due to reach its primary completion in 2027-12. Interventions recorded: AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg). Conditions listed: Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03016819
- Phase: 3
- Setting: A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
- Sponsor: Advenchen Laboratories, LLC
- Enrolled: 325

## Sources

- ClinicalTrials.gov NCT03016819: https://clinicaltrials.gov/study/NCT03016819

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Dacarbazine](https://onco.cc/drugs/dacarbazine/)
- companies: [Advenchen Laboratories](https://onco.cc/companies/advenchen-laboratories/)

---
JSON: https://onco.cc/api/v1/entities/nct03016819.json